U.S. Markets close in 5 hrs 33 mins

OptimizeRx Corp (OPRX) Files 10-K for the Fiscal Year Ended on December 31, 2018

- By insider

OptimizeRx Corp (OPRX) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. OptimizeRx Corp is a technology solutions company serving the healthcare industry. It is engaged in providing consumer and physician platforms. Its core product offering is OPTIMIZERx and SampleMD software application. OptimizeRx Corp has a market cap of $183.600 million; its shares were traded at around $15.25 with and P/S ratio of 9.11. OptimizeRx Corp had annual average EBITDA growth of 23.90% over the past ten years.


For the last quarter OptimizeRx Corp reported a revenue of $6.58 million, compared with the revenue of $4.01 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $21.2 million, an increase of 74.9% from last year. For the last five years OptimizeRx Corp had an average revenue growth rate of 31.2% a year.

The reported diluted earnings per share was 2 cents for the year, compared with the loss per share of $0.12 in the previous year. The OptimizeRx Corp had an operating margin of 0.85%, compared with the operating margin of -17.56% a year before. The 10-year historical median operating margin of OptimizeRx Corp is -21.33%. The profitability rank of the company is 6 (out of 10).

At the end of the fiscal year, OptimizeRx Corp has the cash and cash equivalents of $8.91 million, compared with $5.12 million in the previous year. The company had no long term debt. OptimizeRx Corp has a financial strength rank of 9 (out of 10).

At the current stock price of $15.25, OptimizeRx Corp is traded at 20.5% premium to its historical median P/S valuation band of $12.66. The P/S ratio of the stock is 9.11, while the historical median P/S ratio is 7.55. The stock gained 237.81% during the past 12 months.

For the complete 20-year historical financial data of OPRX, click here.

This article first appeared on GuruFocus.